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Ruthenium-Based Metal-Organic Compounds 
 
Stephanie Roy Farhat 
 
ABSTRACT 
 
Cancer incidence has been increasing worldwide in the last few decades. Solid 
tumors are hard to treat, primarily due to drug resistance as well as to the struggle in 
delivering the drugs specifically to the tumor. Various therapeutic approaches for 
treating solid tumors have been exploited. A very promising approach has been the 
use of Ruthenium-based complexes conjugated to different ligands that are 
characterized by having a photochemical potential rendering them only active after 
exposure to light, which can be ultimately specifically delivered to the site of tumor. 
This study aims to find the most efficient Ru-based compounds on a set of 6 cell lines 
from different solid tumors. Different ruthenium precursors (bis-bidentate), final 
complexes (tris-bidentate) and free phenanthroline- or bipyridine-derived ligands 
were tested. The bis-bidentate complexes tested were four: Ru-I: [Ru(II)(1,10-
phenanthroline)2Cl2]; Ru-II: [Ru(II)(4,7-diphenyl-1,10-phenanthroline)2Cl2]; Ru-III: 
[Ru(II)(4,7-diphenyl-1,10-phenanthroline-disulfonate)2Na2]
2+ and Ru-IV: 
[Ru(II)(2,2'-bipyridine)2Cl2], along with their corresponding free ligands L-I, L-II, L-
III and L-IV, respectively. Ru-II showed significant potency on most of the cell lines 
tested (5 out of 6), as well as Ru-I on two of them while the others were inert. As for 
the free ligands, L-II presented major cytotoxic effect on five out of six cell lines, L-I 
on two cell lines, L-IV on one cell line only. The addition of diphenyl groups to the 
phenanthroline of L-I rendered its structure bulkier and more hydrophobic (L-II), and 
showed an increase in its potent activity, same result when it was bound to the metal. 
Therefore, a structure activity relationship was established between precursors and 
their free ligands. However, when adding sulfonate groups to the 
diphenylphenanthroline structures, the cytotoxic effect is inhibited in the free ligand 
and its precursor, L-III and Ru-III respectively, thus suggesting a possible DNA 
intercalation mechanism of these compounds. On the other hand, neither bipyridine 
nor its corresponding precursor L-IV and Ru-IV, bipyridine and its corresponding 
precursor respectively, shown no cytotoxic activity. In addition, four final compounds 
were synthesized to study the photochemical potential of our metal-based complexes. 
There structure bear combinations of L-II and L-III yielding the tris-bidentate 
compounds, Ru-II3, Ru-II2-III, Ru-II-III2 and Ru-III3, having different net charges 
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ranging between +2 and -4, and their effect was studied in the dark and after exposure 
to blue light. Activity was detected only in Ru-II3 against all the tested cell lines in 
the dark, Ru-II2-III in three cell lines while the others showed no effect. When 
exposed to blue light against the astrocytoma cell line all four compounds showed 
high levels of potency, including Ru-II-III2 and Ru-III3 that were biologically inert 
in the dark. It is hypothesized that these final compounds’ cytotoxic action is due to 
the generation of Reactive Oxygen Species (ROS), causing DNA damage, oxidation 
of amino acids and enzyme co-factors, as well as lipid peroxidation, thus leading to 
cell death. The ultimate goal is to base future selective anticancer treatments using 
Ru-based compounds. The mechanisms by which Ru-based compounds work is still 
being explored, and other ligands and combination of ligands are also being tested to 
find the most selective, and potent complex. 
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CHAPTER ONE 
Introduction 
 
1.1 Solid Tumor Epidemiology 
Statistics measuring cancer mortalities worldwide existed since the emergence of this 
disease. In 2005 for example, around 7.5 million people died of cancer out of 60 million 
deaths worldwide (Gavhan et al., 2011). This study predicted the number of deaths related 
to cancer to be 9 million in 2015. The number of deaths related to cancer has been increasing 
over the past decades reaching 8 million in 2012 (World cancer report, 2014). An estimated 
14.1 million cancer cases were diagnosed around the world in 2012, with the incidence in 
men (7.4 million cases) being slightly higher than the incidence in women (6.7 million 
cases). Statistical projections suggest that this number will reach 24 million by 2035 (Ferlay 
et al., 2015). 13% of the cancer cases in 2012 were diagnosed as lung cancer, making it the 
most common cancer worldwide. Breast cancer was the second most dominant cancer 
worldwide with 1.7 million new cases in 2012 (in women only). And the third most common 
cancer with 1.4 million new cases diagnosed was colorectal cancer (Ferlay et al., 2012). 
 In general, most cancers develop in older people; around 80% of cancers worldwide 
are diagnosed in people of 55 years of age or older (World cancer report, 2014). In addition, 
certain lifestyle aspects can increase the incidence of developing cancer. These include 
smoking, unhealthy diets, and lack of physical activity.  People who smoke, eat an 
unhealthy diet, or are physically inactive also have a higher risk of cancer (Kunnumakkara 
et al., 2008). Probabilities of developing cancer are estimated based on family history, 
genetic susceptibility, and whether the country is a developed or a third world country 
(Parkin et al., 2011). For the majority of cancer types, the risk is higher when the family 
history has a high incidence of this disease. However, many familial cancers do not arise 
exclusively from the genetic makeup of the individual, but from interplay between genetic 
variations, lifestyle, and environmental risk factors (Parkin et al., 2011). 
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1.2 Cancer Overview 
Cancer consists of a family of diseases that share the characteristic of having 
uncontrollably proliferative cells which accumulate several mutations in their genetic 
material. Many factors, external and internal, are causative agents of cancer. External 
factors include chemicals, radiation, tobacco, and some infectious organisms including 
viruses. As for the internal factors, they include hormones, immune conditions, genetically 
inherited mutations, or mutations that occur from cell cycle division and metabolism 
(Parsa, 2012). 
1.2.1 The Progression of Cancer as a Disease 
The transition of cancer cells from a primary tumor to a potential metastasis site 
depends on a series of biological steps. Tumor development is a complex multi-step 
process, with cells evolving progressively from being totally normal, to becoming highly 
malignant (Nimmerjahn et al., 2005). The stages that tissues within a tumor pass through 
in the process of tumor development cause it to be heterogenic because within the same 
tissue, some cells may be in a certain stage, while others are in different stages. 
1.2.1.1 Different Stages of Cancer Growth 
 Hyperplastic growths are characterized by an excessive number of cells (Skarin, 2003). 
Metaplasia refers to the process where a type of a normal layer is replaced by another type, 
such as a squamous epithelium replacing a mucus-secreting epithelium or vice-versa 
(Skarin, 2003). Both hyperplasia and metaplasia are considered minimal deviations from 
normal tissues. Dysplastic tissues bear more cytological abnormalities. The changes in 
these tissues include a variable nuclear size and shape. These changes, along with increased 
mitotic activity, alter the tissues architecture (Skarin, 2003). That’s the reason why 
dysplasia is considered a transitional state between completely benign and premalignant 
growths. The next stage of tumor development is the appearance of macroscopic masses of 
cells such as polyps and warts termed adenomas (Skarin, 2003). These tissues do not invade 
the basement membrane separating them from the underlying stroma because they reach a 
certain size and stop growing. As the cells advance in abnormality stages, they undergo 
several mutations including over expression of some membrane proteases and increased 
mobility (Weinberg, 2013).  
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Figure 1: Overview of cancer metastasis. (McKinnell, 2007) 
 
1.2.1.2 The “Seed and Soil” Theory 
Once the tumor accumulates enough mutations to evade the underlying basal 
membrane and undergo metastasis, it becomes malignant (McKinnell et al., 1998). The 
process of metastasis is extremely complex. The cancer cells should be able to invade 
close-by tissues, migrate through the blood and lymph vessels to distant sites as well as 
having the capacity to leave the vessels and invade basal membranes (Weinberg, 2013). As 
per Doctor Stephen Paget, a surgeon from the late 19th century, cancer metastasis can be 
explained through the “seed and soil” theory. The cancer cell is the seed, and the 
environment where it has an affinity to grow is the soil. Metastasis occurs solely when the 
seed and soil are compatible (Ribatti, 2011). Not any cancer cell can metastasize to any 
tissue. Some cancers are known to metastasize to certain tissues more than others. Breast 
cancer, for example, mostly metastasizes to lung and bone. In contrast, very low metastasis 
events are observed from breast cancer in the spleen and heart (Weigelt et al., 2005). This 
is because the “soil” is not very compatible for cancer cells originating from breast tissues 
in some organs, while it is more compatible in others (Ribatti, 2011).  
1.2.1.3 Cancer Metastasis 
Cancer metastasis is the spread of the cancer cells to organs that are usually distant 
from the site where the tumor was formed. Metastasis is believed to be the cause of death 
of most cancer patients (Connolly et al., 2003). The process of metastasis is composed of 
sequential events that have to be completed so that the tumor cell can successfully 
 4 
 
metastasize. Metastasis adds even more complexity to this multiplex disease. The most 
important and essential events allowing metastasis to occur are changes in cell-cell and 
cell-matrix adhesion (Martin TA et al., 2009). It all starts with the formation of a genetically 
heterogeneous primary tumor which becomes a localized invasion when the tumor evades 
the underlying basal membrane. The tumor cell dissociates from the primary tumor mass 
due to the loss of cell-cell adhesion capacity. The cancer cells then enter into the closest 
blood vessels and then interact with the platelets, lymphocytes, and other blood 
components through a process called intravasation. Even if the primary tumor was 
removed, some metastatic cells are able to disseminate to subsequently form 
micrometastasis. To do so, these cells must be transported through circulation to different 
parts of the body. Some of the cells arrest in the capillaries and microvessels of many 
organs. Extravasation of cancer cells then takes place initiating the formation of a 
micrometastasis. Some of the cells, mainly the ones that acquired enough mutations, will 
gain the ability to colonize and form a macroscopic metastasis. To do that, the tumor must 
induce angiogenesis to assure a potential source of oxygen and nutrients. This large mass 
of cells will undergo a new secondary wave of metastatic dissemination, forming new 
micrometastasis which in turn form multiple macroscopic metastasis. This is thought to be 
the mechanism by which most cancers are able to relapse after treatment or removal of the 
primary tumor (Weinberg, 2013).  
 
   
 
1.3 Tumor Physiology 
Solid tumors are lumps of genetically, morphologically, and functionally abnormal 
cells. The unique physiology of solid tumors comes mainly from the vasculature that is 
composed of two types of vessels: the existing vessel that used to nourish the normal tissue 
before tumor cells took over, and the microvessels arising from neovascularization caused 
by proangiogenic factors produced by cancer cells (Brown et al., 1998). Although having 
the same structures as blood vessels found in other body parts, tumor blood vessels are 
irregular in shape, have arterio-venous shunts, blind ends, and they lack smooth muscle, 
making them much leakier than other vessels (Ribatti 2011).  
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Figure 2: Normal vasculature VS vasculature of a tumor cell. (Brown et al., 2004) 
1.4 Types of Cancers Arising from Solid Tumors and Respective Cell 
Lines 
1.4.1 Lung Cancer 
Lung cancer is a cancer that usually forms in the tissues lining the air passages. Two 
main types of lung cancers are small cell lung cancer (SCLC) and non-small cell lung 
cancer (NSCLC). These two types are distinguished based on the morphologies of the cells 
observed under the microscope. Lung cancer constitutes a major worldwide health problem 
since it causes around 18% of deaths worldwide (Hoffman PC et al., 2000). Around 
220,000 cases of lung cancer were expected in 2015, constituting about 13% of all 
diagnosed cancers (Cancer.org). The most important risk factor for lung cancer is cigarette 
smoking mainly, but other environmental factors such as pollution, as well as professions 
where exposure to different chemicals occurs (deGroot et al., 2012). The risk of developing 
lung cancer increases also with family history and among individuals with a medical 
history of tuberculosis (Cancer.org). Symptoms of lung cancer are respiratory such as 
coughing up blood and shortness of breath, systemic such as weakness and fever, and 
symptoms caused by the tumor pressing on adjacent tissues such as chest pain, bone pain, 
and difficulty of swallowing (Horn et al., 2015). Many panel cancer cell lines are used in 
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the lab. A549 cells are adenocarcinoma human alveolar basal epithelia cells. These cell 
lines were first developed by the culturing of a cancerous lung tissue transferred from an 
elderly Caucasian male (Giard et al., 1973). The primary function of these cells are 
diffusion and osmosis across alveoli. In vitro, these cells form a monolayer and grow 
adherent to the flask (Giard et al., 1973). High levels of unsaturated fats are found in A549 
cell lines; these are crucial to maintain the membrane phospholipids. (Giard et al., 1973). 
1.4.2 Breast Cancer 
Breast cancer is the most common type of cancer in women worldwide (McGuire et 
al., 2015). The variability of breast cancer incidence around the world is huge; its incidence 
is the lowest in less-developed countries, and it increases in the most developed countries 
(Stewart et al., 2003). The risk factors of breast cancers are numerous: breast cancer 
incidence increases in females and in elderly people (Yager et al., 2006). In addition to 
genetic factors, lack of breastfeeding appears to induce higher levels of certain hormones, 
increasing the incidence of breast cancer in women (Santoro et al., 2009). Plus, recently, 
light pollution has been indicated an important risk factor for the development of breast 
cancer (Portnov et al., 2013). Symptoms of breast cancer are visually noticeable. They 
include a lump with a different texture than the rest of the breast tissue, thickening of a 
breast, a rash around a nipple, discharge from nipples, and sometimes a change in shape or 
position of a nipple is detected (Watson, 2008). Breast cancer is known to metastasize 
occasionally and spread beyond the breast. Most common sites of metastasis include lung, 
liver, bone, and mostly brain (LaCroix, 2006). Different panels of breast cancer cell lines 
including MCF-7 and MDA-MB231 are used in the labs. MCF-7 is a breast cancer cell line 
isolated from an elderly Caucasian women. It is named after the institute where the cell 
line was first established: Michigan Cancer Foundation-7 (Soule et al., 1973). MCF-7 are 
primary invasive breast ductal carcinoma, bearing estrogen receptors and highly 
tumorigenic (Levenson et al., 2007; Ross et al., 2001). In addition to MCF-7, two other 
breast cancer cell lines account for over 60% of research done on breast cancers: these are 
T-47D and MDA-MB-231 (LaCroix, 2004).  
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1.4.3 Colorectal Cancer 
Colorectal cancer is diagnosed in 1 million cancer patient each ear, and is responsible 
of about 750,000 deaths since 2010 (Cunningham et al., 2010). Its incidence is higher in 
developed countries than in developing countries: Colorectal cancer incidence is 10-fold 
higher in Europe and Australia than in Africa and South-Central Asia (Ferlay et al., 2010). 
The incidence of colorectal cancer increases with patients suffering from inflammatory 
bowel disease, and with the cancer being diagnosed in the family, especially in first-degree 
relatives (Jawad et al., 2011; Cunningham et al., 2010). The symptoms of colorectal cancer 
largely depend on the precise location of the tumor. However, most common signs include 
nausea, vomiting, constipation, blood in stool and rectal bleeding, especially in individuals 
above 50 years old (Alpers et al., 2008; Astin et al., 2011). Caco-2 is an example of a 
continuous heterogeneous human epithelial colorectal adenocarcinoma cells (Fogh et al., 
1975). In vitro, these cells form a monolayer that allows the passage of electrolytes and 
small molecules (Hidalgo et al., 1989). And when cultured under specific conditions, these 
cells differentiate and polarize such as their morphology and function becomes similar to 
that of the enterocytes of the small intestine, expressing tight junctions, microvilli and 
numerous enzyme transporters (Pinto, 1983; Hidalgo et al., 1989). Comparing results of 
experiments done on Caco-2 cell lines between labs is difficult due to the heterogeneity of 
these cells (Sambuy et al., 2005). 
1.4.4 Melanoma 
Skin cancer is a common type of cancer that resulted in around 80,000 death a year 
since 2010 (Lozano, 2012). It is more common in Australia and New Zealand, reaching 
around 4-fold higher incidence than in the United States (Jones et al., 1999). Although the 
incidence of skin cancer has been increasing over the past few years, the survival rate of 
melanoma patients is relatively high (Skin cancer facts, 2016). It mainly depends on the 
stage that the cancer reaches when they start treatment (Skin cancer facts, 2016). The 
incidence of skin cancer increases with HPV infections (mainly increasing the risk of 
squamous cell carcinoma), Marjolin’s ulcers (chronic non-healing wounds), and most 
importantly, the exposure to ionizing radiation, UV radiation, and environmental 
 8 
 
carcinogens (Saladi et al., 2005; Amdt, 2010). Skin cancer types include basal-cell 
carcinoma, squamous-cell carcinoma, melanoma, and Merkel cell carcinomas. The most 
common symptoms is formation of skin ulcers (What You Need To Know About 
Melanoma And Other Skin Cancers, 2010; Bickie et al., 2004). Different cell lines are 
derived from a range of skin cancer types. These include, but are not limited to 721 
melanoma cell line, FM3 melanoma cell line, and B16 melanoma cell lines. B16 cell lines 
are extracted from mice and are highly variable, even within the same lab; they can change 
in the metastatic potential and tumorigenic dose (Overwijk et al., 2001).  
1.4.5 Astrocytoma 
Astrocytoma is a type of brain cancer that originates in a particular kind of start-shaped 
glial cells called astrocytes. Cancers that originate in the brain constitute around 1.4% of 
all cancers and are responsible for 2.3% of deaths related to cancer. Brain cancer usually 
interferes with the normal brain functions and affects areas of the brain that have critical 
role in the function of the brain (El-Zein et al., 2002). The incidence of astrocytoma 
increases with ionizing radiation. In addition to environmental factors, genetic risk factors 
also increase the risk of astrocytoma; these include mutations passed from a generation to 
another. These mutations are known to cause abnormal cell growth and proliferation 
leading to the development of a tumor (Stupp et al., 2007). The symptoms of astrocytoma 
are due to the pressure growing inside the skull. Other symptoms include drowsiness, eye 
swelling. The symptoms of astrocytoma depend on the part of the brain where the tumor 
grows. This can sometimes be determined by the nature of the seizures that a cancer patient 
suffers from (Smith et al., 2001). Experiments are done on different cell lines to try to get 
a better knowledge of astrocytoma. SF268 cell lines are an example. They were first 
harvested from the right parietal lobe of a 24 year old brain cancer patient. They are highly 
anaplastic and relatively hard to grow (Westphal et al., 1985). 
 
1.5 Main Approaches in Treating Solid Tumors 
1.5.1 Surgery 
Surgery is the first cancer treatment developed and the most frequently used to inhibit 
small tumors from developing into larger ones. It involves resecting primary tumors aiming 
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to reducing metastatic relapse risks. The earlier the tumor is detected, the higher chances 
to remove the tumor without extending the surgical margins (Weinberg, 2013). However, 
during the excision process, a part of the tumor’s surrounding is also removed because 
most malignant solid tumors spread through the lymphatic system, hence most regional 
lymph nodes are eliminated. In addition, tumor resection helps in pain relief, decreases the 
occurrence of life-threatening bleedings, and relieves compressions of many vital organs 
(brain, spinal cord, trachea …), helping the organs to regain their function and avoiding 
distressing symptoms. Subsequently, the margins of the tumor are the biggest challenges 
of the surgical method; this requires the use of an adjuvant therapy such as chemotherapy 
or radiation (Reson, 2008).  
1.5.2 Radiation Therapy 
Radiation therapy is a cancer treatment strategy that went into clinical trials after World 
War II, after discovering the possibility to direct X-rays at narrow fields of radiation to 
target primary tumors without affecting normal tissue. It is mainly used to treat localized 
solid tumors when surgery is not feasible. Ionizing radiation kills cancer cells by 
transferring energy to tissues, discarding electrons from biologically important molecules 
like DNA. This breaks the DNA strand and stops its replication during mitosis. Extensive 
DNA damage leads to apoptosis (Birgisson et al, 2007). 
1.5.3 Chemotherapy 
The most common approach for treating different cancers is chemotherapy. In most 
cases, it is combined with surgery or radiation. Chemotherapy is more recent than the other 
techniques as it emerged in the 1940s after discovering antimetabolites that interfere with 
the normal function of enzymes producing metabolites in the cells. These include purine 
or pyrimidine analogs that incorporate themselves during DNA synthesis thereby 
disrupting the normal DNA biosynthesis (Choi et al., 2008). Aside from purine and 
pyrimidine analogs, antimetabolites can interfere with microtubule assembly and are 
effective as anti-cancer agents. These work by blocking microtubule breakdown at the end 
of mitosis. Others work the opposite direction, by preventing the initial assembly of 
microtubules. Antimetabolites interfering with microtubules assembly and breakdown are 
mainly used to treat different lymphomas, lung cancers, and squamous cell carcinomas 
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(Weinberg, 2013). Chemotherapeutic agents directly damage DNA, interfering with cell 
division and as a result leading to apoptosis. Other chemotherapeutic agents sequester 
nucleotides in a way to block DNA synthesis. The reason why chemotherapy is very 
common is because approaches, using one or multi-agent therapies appear to be applicable 
even in cancer patients who are above 80 years old (Coluccia et al., 1993). Over the past 
20 years, chemotherapy has evolved from being a potentially toxic treatment to one that is 
resulting in significantly positive results. However, chemotherapy has been showing 
numerous limitations. These include but are not limited to: 
1- Toxicity: chemotherapy can injure normal tissues, especially the ones that contain cells 
that divide more frequently than others such as bone marrow, gonads, and hair follicles, 
thereby the side effects become predictable: Nausea and vomiting, hair loss, stomatitis, 
diarrhea, and myelosuppression. Plus, the irony of cancer treatments that is also found in 
radiation therapy is that most agents used are carcinogens themselves (Gavhane et al., 
2011).  
2- Poor penetration of the drugs in solid tumors: The safe and efficient doses of anticancer 
drugs are usually hard to reach, since most of these agents require high concentrations to 
be efficient, that they become dangerous when treating patients. In addition, the unusual 
vascularization of tumors is a factor that limits the uptake of the chemotherapeutic agents 
(Dreicer et al., 2008; Kovacs et al., 2007). 
3- Tumor drug resistance: malignant cells have tendency to resist drug administration. They 
mainly do so by pumping the drug out of the cell through overexpressing membrane 
glycoproteins (a non-specific mechanism that can confer resistance to any type of drug), 
thereby limiting the effectiveness of anticancer agents in general, rather than 
immunotherapy alone (Gavhane et al., 2011).  
1.5.4 Metal-Based Compounds in Cancer Therapy 
Metal-based compounds have been known since ancient Egyptians used gold salts as 
potential anti-disease agents (Nobili et al., 2010). Traditional Chinese medicine also uses 
arsenic trioxide (ATO) as antiseptic agents for diseases such as syphilis, rheumatoid 
arthritis and psoriasis. These were also used for treatment against leukemia in the 18th and 
19th centuries (Dilda et al., 2007).   
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1.5.4.1 Cisplatin in Cancer Therapy 
In 1969, cisplatin was discovered as an antibacterial agent that was essential in the 
formation of platinum electrodes and eventually showed potency against tumors 
(Weinberg, 2013; Rosenberg et al., 1969). Cisplatin itself generates covalent intra-strands 
cross links in DNA, usually between 2 adjacent guanines generating a significant bent in 
the DNA (Hannon, 2007). Cisplatin is a molecule bearing a Pt(II) metal center connected 
to 2 molecules of ammonia and 2 chloride atoms in a cis conformation (figure 4). After 
injection in the serum, cisplatin remains in its neutral form. However, once it is inside the 
cell, one or both Cl ligands can be dislodged by one or two water molecules, thus attributing 
a cationic charge to cisplatin and abolishing its neutral state. This new cationic complex 
interferes with nucleotides, specifically with the N7 of guanine and adenine. In most cases 
(70%), the intercalation of cisplatin moves 2 adjacent bases on the same strand in a 
bifunctional manner, creating a 45o nick in the DNA double strand; this is called the G-G 
1,2 intra-strand adduct (Takahara et al., 1995). As with any anticancer agent, cisplatin is 
not free of adverse effects that are believed to be due to the platination of sulfur residues 
on proteins. These side effects include nephrotoxicity, nausea, and numbness of the limbs. 
Fortunately, they can be encountered by the use of sulfur-rich “rescue agents” (Hannon, 
2007). 
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 Figure 3: Original cis-platinum compounds. (Hannon, 2007) 
 
The cis conformation of cisplatin played an important role in its potency, unlike the 
trans conformation, which led to the use of the square-planer Pt(II) center connected to 2 
amino groups in a cis conformation, along with 2 good relatively leaving groups such as 
chloride ions. This form seems to be the most efficient, and led to many derivatives 
including carboplatin, nedaplatin, and oxaliplatin (figure 4). These agents were able to 
make it to the market. Later on, it was shown that the exact structure described previously 
was not mandatory for activity; compounds with trans conformation were shown to be 
efficient also, even though they do not follow the classical structure-activity relationship 
depicted with cis conformations (Hannon, 2007; Jakupec et al., 2005). These non-classical 
agents include 3 different classes of trans-platinum (II) complexes: The first class contains 
pyridine ligands, the second contains an isopropylamine and an alkylamine, and the third 
contains iminoether ligands Hannon, 2007; Farrell et al., 1989; Montero et al., 1999; 
Coluccia et al., 1993). These unconventional trans-platinum agents showed, in addition to 
their in-vitro activity similar to cisplatin, an activity against cell lines that were resistant to 
it. Moreover, the types of DNA lesions caused by cisplatin are constitutionally different 
from those caused by the trans conformation (Hannon, 2007). 
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Figure 4: Classes of active unconventional trans-platinum (II) complexes. 
Left: pyridine-containing; Middle: isopropylamine-containing; Right: iminoether-containing. (Hannon, 2007) 
 
 Another class of active unconventional platinum agents includes the di- and tri- 
platinum compounds that were developed by Farrel in 2004. In these molecules, the metal 
centers are connected by flexible diamine chains. These compounds have poly-cationic 
characteristics in addition to having more than one nucleus, and do not contain platinum 
centers with cis leaving groups. This class of compounds showed increased activity 
relatively to cisplatin against numerous cell lines including those that were resistant to 
cisplatin. They induce their effects by generating intra- and inter-strand long range 
bifunctional moves. They also showed a high ability in changing the DNA from being 
right-handed (B) to left-handed (Z) (Kloster et al., 1999).  
 The newer-generation metal based compounds are platinum analogs named oxaliplatin 
and carboplatin. These, and cisplatin constitute some of the most important chemotherapic 
agents (Kelland, 2007; Jungwirth et al., 2011). Cisplatin made a huge success in the fields 
of cancer therapies. An example would be its effect on the cure rate for testicular cancer: 
prior to the use of carboplatin, a drug derived from cisplatin, only 10% of testicular cancers 
were cured. After the use of cisplatin-related agents, the cure rate of this cancer increased 
to 95% (Weinberg, 2013).  
1.5.4.2 Non-Platinum-Based Compounds in Cancer Therapy 
Following this remarkable success, researchers decided to explore other compounds 
based on several metals mainly gold, titanium, vanadium, cobalt, and ruthenium, and are 
currently yielding satisfying outcomes in clinical trials (Jungwirth et al., 2011).  
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Non-platinum metal-based compounds have been explored ever since cisplatin 
showed positive results. Among these, those with Ruthenium center were the subject of 
interest. They had significant anti-cancer activity and numerous benefits:  
 Its ability to coordinate with different ligands allows the synthesis of a wide array 
of new complexes. 
 Its rate of ligand exchange is comparable to that of platinum. 
 Unlike Platinum, that has a planar geometry, Ruthenium forms an octahedral 
geometry when bound to ligands, thereby having different mode of function than platinum. 
 Under physiological conditions, Ruthenium has 3 oxidation states (+II, +III, and 
+IV), allowing it to form pro-drugs at the +III oxidation state that can be reduced once the 
target is reached. 
 Finally, Ruthenium has the ability to mimic iron and bind to albumin and 
transferrin, thus reducing its cytotoxic effects compared to Platinum (Hannon, 2007; 
Jakupec et al., 2005; Jungwirth et al., 2011; Bergamo et al., 2012). 
 
Ruthenium-Based Compounds 
Ruthenium based compounds are administered at first as Ru(III) compounds and 
once the target is reached, they get reduced to the Ru(II) oxidation state and become more 
kinetically reactive, following a process called “activation by reduction”. This lowers the 
toxicity of most ruthenium-containing compounds. This is thought to occur in the reductive 
environment of the proliferating hypoxic cells in the core of the solid tumor where 
inadequate angiogenesis is present (Jakupec et al., 2005; Schluga et al, 2006).  NAMI-A 
and KP1019 (figure 6) are the 2 Ru(III) compounds that are currently under clinical trials. 
NAMI-A, the first to enter clinical trials is an anionic complex bearing an octahedral 
geometry: the center of this molecule, (Ru(III)), is connected to one DMSO and one 
imidazole ligands, along with 4 chloride ions. NAMI-A was active against cancer cell lines 
and more importantly had a significant effect on metastasis (Hannon, 2007). NAMI-A’s 
mechanism of action when binding to DNA is different than other Ru-based complexes. It 
possesses anti-angiogenic activities through scavenging liberated nitric oxide (NO) from 
epithelial cells, as well as anti-invasive properties that originate from the interaction of 
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NAMI-A with extracellular membrane receptors (Bergamo et al., 2012;  Jungwirth et al., 
2011). 
 
Figure 5: NAMI-A and KP1019 structures. (Bergamo et al., 2012) 
  
Ruthenium and Photodynamic Therapy 
Photodynamic therapy (PDT) is a technique that relies on activating photosensitive 
agents by light in order to kill cancer cells. Their activity is determined by the type of 
interaction between the PDT agents and the components of the tumor cell (DNA, cell 
membrane, proteins, biopolymers…). One example of the PDT’s mechanism of action is 
damaging DNA through electron transfer from the excited state of the PDT to DNA. 
Another example is substituting ligands in a way to make the complex release a 
biologically active molecule or itself binding to the target molecule after photo-activation 
(Clarke, 2003). The complexes that are inert in the dark are more efficient in PDT since 
they display larger phototoxicity indices. Ideally, these complexes should readily switch 
from the ground state to excited state in the photodynamic therapy window (Clarke, 2003). 
PDT applied in anticancer approaches primarily target DNA through several mechanisms: 
non-covalent hydrophobic interaction and covalent binding, DNA intercalation, and the 
binding between a positively-charged complex and DNA (Manning, 1978; Manning et al., 
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1998;  Yang et al., 1997) Ru(II) complexes connected to N-heterocyclic ligands can be 
efficient PDT agents since they can have long-lasting excited states and because of their 
fast metal-to-ligand charge transfer transitions (Clarke, 2003; Pacor, 1991).   
1.6 Study Objectives 
The purpose of this study is to test the effect of Ru(II) metal-based compounds bound 
to N-heterocyclic ligands against  solid tumor cell lines in order to establish a 
photochemical model related to these compounds. This will be done by first, studying the 
relationship between structure and activity of the Ru(II) based compounds, relating that to 
their potency against different solid tumor cell lines. Second, once the compounds show 
efficiency in killing cancer cells, the type of cell death will be determined. Third, to detect 
if these compounds possess any photochemical potential, they will be photo-activated once 
applied to the different solid tumor cell lines, and the type of cell death will be eventually 
determined. Finally, the goal of this research project is to provide an initiative for future 
approaches targeting some solid tumors. 
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CHAPTER TWO 
Materials and Methods 
2.1 Cells and Cell Lines 
Human solid tumor cell lines Astrocytoma cells (SF), Melanoma (B16), Human 
Breast Adenocarcinoma cells (MDA-MB-231, MCF-7), Colorectal cells (CaCo-2) and 
Lung carcinoma cells (A549) were obtained from the American Type Culture Collection 
(ATCC) and grown as described previously in DMEM 1640 supplemented with 10% FBS 
and 5% Penicillin/Streptomycin at 37°C, 5% CO2 (Pellizzari et al., 1999). 
2.2 Compounds 
Compounds were synthesized by Dr. Rony Khnayzer and his research group at the 
Lebanese American University. They were provided in the lyophilized powder form, 
dissolved and aliquoted in stocks of 1, 2, 5 or 10 mM in DMSO. Aliquots were stored at -
80°C for a maximum of 2 months or 3 freeze-thaw cycles. 
 
Figure 6: Ligands, ligand-free Ru(II) control and Ru(II) precursor complexes. 
Ligands: L-I: 1,10-Phenanthroline; L-II: 4,7-Diphenyl-1,10-phenanthroline; L-III: 4,7-Diphenyl-1,10-phenanthroline 
disulfonic acid; L-IV: 2,2-Bipyridine; Ligand-free Ru(II) control: Ru-C: RuCl2(DMSO)4; Ru(II) precursor complexes: 
Ru-I: [Ru(II)(1,10-phenanthroline)2Cl2]; Ru-II: [Ru(II)(4,7-diphenyl-1,10-phenanthroline)2Cl2]; Ru-III: [Ru(II)(4,7-
diphenyl-1,10-phenanthroline-disulfonate)2Na2]2-; Ru-IV:[Ru(II)(2,2'-bipyridine)2Cl2]. 
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Figure 7: Different structures of the photochemically-active Ru(II) final (Tris) complexes. 
Ru-II3: [Ru(II)(4,7-diphenyl-1,10-phenanthroline)3]2+; Ru-II2-III: [Ru(II)(4,7-diphenyl-1,10-phenanthroline)2(4,7-
diphenyl-1,10-phenanthroline-disulfonate)]; Ru-II-III2: [Ru(II)(4,7-diphenyl-1,10-phenanthroline)(4,7-diphenyl-1,10-
phenanthroline-disulfonate)2]2-; Ru-III3: [Ru(II)(4,7-diphenyl-1,10-phenanthroline-disulfonate)3]4-. 
2.3 Metal Uptake by Flow Cytometry 
Cellular uptake of auto-fluorescent Ru-containing complexes was measured by flow 
cytometry. The SF cells were plated in 24-well plates at a density of 2.5 x105 cells in 250 
µL cell culture medium in each well. The cells were allowed to recover for 24h at 37°C/5% 
CO2, then 250 µL of compounds diluted in medium were added. The plates were incubated 
at 37°C with 5% CO2 for the needed amount of time before being harvested and run for 
fluorescence detection on the FL3-H channel on a C6 flow cytometer (BD Accuri, Ann 
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Arbor, MI). The threshold was set to 500,000 on FSC-H, and 5,000 to 20,000 events were 
run per sample. 
2.4 Proliferation Inhibition Assay (Cytotoxicity) 
Sensitivity of the used cell lines to the compounds listed above was determined using 
a proliferation inhibition assay. Briefly, aliquots of 2 to 3 x104 cells/well in 100 µL of cell 
culture medium were plated in a flat-bottom 96-well plate (Corning Inc. Corning, NY). 
The cells were allowed to recover for 24h, before 50 µl of compound in media were added 
to each well to yield concentrations ranging from 200 µM to 3 nM. In the experiments 
involving light activation, the plates containing cells and compounds were exposed to blue 
light (430-490 nM) at 10 V for 30 min at room temperature. Following an incubation at 
37°C/5% CO2 till the appropriate time-point of the experiment, 10 µL of WST cell 
proliferation reagent (Roche, Basel, Switzerland) were added to each well 2h before the 
end of the intended incubation period, and the cells were incubated as above for the 
remaining 2h. Absorbance was then read at 450 nm using a microplate reader (Thermo 
Fisher Scientific, Waltham, MA). Nominal absorbance and percent maximal absorbance 
were plotted against the log of concentration and a non-linear regression with a variable 
slope sigmoidal dose-response curve was generated along with IC50 using GraphPad Prism 
5 software (GraphPad Software, San Diego, CA).  
2.5 Type of Cell Death Determination 
The type of cell death was determined using fluorescin Isothiocyanate (FITC)-
conjugated Annexin V antibody (Annexin V-FITC) and PI staining (apoptosis detection 
kit, Abcam, Cambridge, MA) as described previously (Abi-Habib et al. 2005). Annexin V 
is a calcium-dependent phospholipid binding protein specific to Phosphatidylserine (PS). 
PS is a component of the phospholipid membrane that, under normal conditions, faces the 
cytosolic side of the membrane due to the activity of the enzyme flippase. During 
apoptosis, flippase loses its activity on PS, allowing it to spontaneously flip and face the 
extracellular domain. As a result, macrophages recognize and engulf the cell. When the 
cells die, their cytoplasm becomes permeable to Propiduim idodide (PI), an auto-
 20 
 
fluorescent DNA intercalating agent that can be detected using flow cytometry on the FL2-
channel (y axis). As for Annexin V, it can be detected using flow cytometry on the FL1-H 
channel (x axis). To differentiate between late-apoptosis and necrosis, caspase cascade 
activity is tested. To do so, an approach that uses flow cytometry called fluorescence 
inhibition of caspase is used. A fluorescent pan caspase inhibitor binds to reactive cysteine 
residues of active caspases and the levels of fluorescent caspase inhibitors are measured 
FL1-H channel (x axis). 
The presence of active caspases in SF268 cells was detected using a cell permeable, 
FITC-conjugated active caspase inhibitor (R&D systems) on flow cytometry as described 
previously (Abi-Habib et al, 2005). Briefly, 3x105 cells/well were plated in 250 µL of 
culture medium in a 24-well plate and were left to recover for 24 hours at 37°C/5% CO2. 
They were later incubated with either 250 µL of media alone (control cells) or media 
containing different concentrations of L-II, Ru-II, Ru-II3, Ru-II2-III, Ru-II-III2 and Ru-III3 
for 24, 48 and/or 72 hours at 37°C/5% CO2. In the experiments involving light activation, 
the plates containing cells and compounds were exposed to blue light (430-490 nM) at 10 
V for 30 min at room temperature. Cells were then either harvested and incubated with 
FITC-conjugated annexin V antibody (2.5 mg/ml) and PI (5 mg/ml) in antibody binding 
buffer for 45 minutes at 37°C, or incubated with a FITC-conjugated active caspase inhibitor 
(ApoStat Apoptosis Detection Kit, R&D Systems, Abingdon, England) for 60 minutes then 
harvested. Cells were then read using a C6 flow cytometer (BD Accuri, Ann Arbor, MI). 
Annexin V/PI data was analyzed on FL1-H versus FL2-H scatter plot and caspase 
activation was detected on FL1-H. Unstained cells were used as negative control. Cells 
were gated on width versus forward scatter. Cells had to show positive annexin V staining, 
negative PI staining and positive active caspase staining to be considered apoptotic, while 
cells positive for both annexin V and PI staining and negative for active caspase staining 
were considered non-apoptotic/necrotic. 
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2.6 Cell Cycle Analysis 
The impact of Ru-II3, Ru-II2-III, Ru-II-III2 and Ru-III3 treatment in the dark and light on 
the cell cycle of SF cells was determined using Propidium Iodide (PI)-staining on flow 
cytometry as described previously (Abi-Habib et al, 2005). Briefly, cells (106 cells/well 
in 1 mL growth medium) incubated with different concentrations of L-II, Ru-II, Ru-II3, 
Ru-II2-III, Ru-II-III2, Ru-III3 or media alone in 6-well plates (Corning Inc. Corning, NY) 
for 72 hours at 37°C/5% CO2, were harvested and fixed in 70% ethanol for a minimum of 
24 hours at -20°C. In the experiments involving light activation, the plates containing 
cells and compounds were exposed to blue light (430-490 nM) at 10 V for 30 min at 
room temperature before the harvesting step. Cells were then incubated in 500 µL PI 
staining solution (50 μg/ml) for 40 minutes at 37°C. Samples were then read on a C6 
flow cytometer (BD Accuri, Ann Arbor, MI) and cell DNA content was measured on 
FL2-A. The target cell population, excluding fragments and doublets, was gated on width 
versus forward scatter. Percent of cells in G0/G1, S and G2/M phase as well as percent 
cells in pre-G0/G1 phase (dead) was determined in control cells and in cells treated with 
the different concentrations of Ru-II3, Ru-II2-III, Ru-II-III2 and Ru-III3 at the different 
time points. 
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CHAPTER THREE 
Results 
 
3.1 Cellular uptake of the Ru-II Precursor Complex  
Testing the uptake of Ru-II was done by using the flow cytometry assay after treating 
SF268 cell line. This compound itself is auto-fluorescent and can be detected on the FL3-
H channel, and its uptake was detectable at early time points after treatment of the cells (30 
min and 60 min), as well as at later time points (2h, 4h, 6h and 24h) (figure 14). The uptake 
was significant at the late time points, starting 4h and up posttreatment. Thus, deducing 
that the uptake of the compound is necessary for inducing a cytotoxic effect in the cells. 
 
 
Figure 8: Detection of cellular uptake of Ru-II at early and late time points after treatment of SF268 cell line. 
Ru-II found intracellularly through flow cytometry on FL3-H at 0.5, 1, 2, 4, 6 & 24h post treatment. The emission 
fluorescence is near 600 nm. 
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3.2 Cytotoxic Effect of the Ligands and Ru(II) Precursor Complexes on 
Human Solid Tumor Cell Lines 
The Ru(II) precursor complexes were tested on 6 different solid tumor cell lines, 
along with their respective free ligands which are derivatives of phenanthroline and 
bipyridine. In figure 8, data showed that L-I and Ru-I had no significant effect on the cell 
lines except B16 and MDA-MB-231. However, all cell lines were sensitive to L-II and Ru-
II as depicted in figure 9. L-III, Ru-III, L-IV and Ru-IV showed no potency on the cell 
lines except for L-IV showing significant potency against B16 cell line (figures 10 & 11). 
As for the ligand-free metal control Ru-C, data from figure 12 showed no toxicity on the 
tested cell lines. IC50 averages were calculated and only the compounds that showed 
potency were summarized in table 1.  
 
Figure 9: Cytotoxic effect of the free ligand L-I and its corresponding precursor complex Ru-I on 6 
representative Solid Tumor cell lines at 48h. 
Nonlinear regression curves for the cytotoxicity of L-I & Ru-I vs DMSO (solvent) on A549, B16, Caco2, MCF-7, 
MDA-MB-231 and SF268, respectively.  Percentage of v/v DMSO is 2% at the highest dosage of each tested 
compound. 
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Figure 10: Cytotoxic effect of the free ligand L-II and its corresponding precursor complex Ru-II on 6 
representative Solid Tumor cell lines at 48h. 
Nonlinear regression curves for the cytotoxicity of L-II & Ru-II vs DMSO (solvent) on A549, B16, Caco2, MCF-7, 
MDA-MB-231 and SF268, respectively.  Percentage of v/v DMSO is 2% at the highest dosage of each tested 
compound. 
 
 
 
Figure 11: Cytotoxic effect of the free ligand L-III and its corresponding precursor complex Ru-III on 6 
representative Solid Tumor cell lines at 48h. 
Nonlinear regression curves for the cytotoxicity of L-III & Ru-III vs DMSO (solvent) on A549, B16, Caco2, MCF-7, 
MDA-MB-231 and SF268, respectively.  Percentage of v/v DMSO is 2% at the highest dosage of each tested 
compound. 
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Figure 12: Cytotoxic effect of the free ligand L-IV and its corresponding precursor complex Ru-IV on 6 
representative Solid Tumor cell lines at 48h. 
Nonlinear regression curves for the cytotoxicity of Ru-C vs DMSO (solvent) on A549, B16, Caco2, MCF-7, MDA-
MB-231 and SF268, respectively.  Percentage of v/v DMSO is 2% at the highest dosage of each tested compound. 
 
 
Figure 13: Cytotoxic effect of the ligand-free Ru(II) metal core on 6 representative Solid Tumor cell lines at 48h. 
Nonlinear regression curves for the cytotoxicity of Ru-C vs DMSO (solvent) on A549, B16, Caco2, MCF-7, MDA-
MB-231 and SF268, respectively.  Percentage of v/v DMSO is 2% at the highest dosage of each tested compound. 
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Table 1: Average IC50 (µM) at 48h 
 L-I Ru-I L-II Ru-
II 
L-
IV 
A549 63 62 22 38 >200 
B16 21.5 21 28 27.5 4.5 
Caco2 140 >200 20 30 >200 
MCF-7 >200 >200 37.5 27 >200 
MDA-MB-
231 
31 12.5 24.4 22 >200 
SF268 63 107 4 5 105 
 
 
Figure 14: Ru-I shows high potency against MDA-MB-231 cell line, L-II and Ru-II against SF268 cell line, L-IV 
against B16 cell line and the ligand-free Ru-C is biologically inert. 
IC50 (µM) at 48h of the different compounds obtained from 6 solid tumor cell lines.  
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3.3 Type of Cell Death Determination of the Action of the Free L-II 
Ligand and Ru-II Precursor 
 
One method to determine the type of cell death involves Annexin V labeled with a 
fluorescent probe. As a result, cells that stain negative for Annexin V and PI are the healthy 
population, cells staining positive for Annexin V and negative for PI are cells undergoing 
apoptosis, whereas cells staining positive for both are late-apoptotic cells and the cells 
positive for PI stain only are necrotic.  
Flow cytometry is used to determine the type of cell death of SF268 cell line when 
treated with L-II and Ru-II at 24h and 48h. These are non-conclusive results and this 
experiment is still under process (Figures 15 & 16). However, from these preliminary data, 
at 24h no cell death is observed by L-II and Ru-II, same goes for Ru-II at 48h. On the other 
hand, in the case of L-II at 48h, small traces of late-apoptotic cell death is shown by these 
cells, however the values are non-significant (control; 2.2%; treatment with low 
concentration: 5.9%; treatment with high concentration: 7.3%).  
As for the caspase assay at 48h, for both compounds, L-II and Ru-II, data showed 
lack of caspase cascade activation meaning no detection of apoptosis. 
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 Figure 15: Preliminary results of the type of cell death caused by L-II. 
Annexin-PI (1A –1C & 2A-2C) & Caspase Activation (D) at 48h. SF268 Control (1A & 2A). L-II – 4.5 µM (1B & 1C) 
& 9 µM (2B & 2C). Normal cell population (LL), early-apoptotic cell population (LR), late-apoptotic / necrotic cell 
population (UR). 
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Figure 16: Preliminary results of the type of cell death caused by Ru-II. 
Annexin-PI (1A –1C & 2A-2C) & Caspase Activation (D) at 48h. SF268 Control (1A & 2A). Ru-II – 5 µM (1B & 1C) 
& 10 µM (2B & 2C).  
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3.4 Cellular uptake of the Final (Tris-) Complexes in the Dark 
Intracellular levels of uptake, as described above, were observed for all 4 compounds 
at early and late time points post-treatment in SF268 cell line. The data of Ru-II3 & Ru-II2-
III were only shown (Figures 24 & 25), where significant cellular uptake was detected at 
the late time points. In the case of Ru-II3, it was detected at 60 min posttreatment, whereas 
for Ru-II2-III, it was detected 2h after treating the cells. Same results were obtained for Ru-
II2-III & Ru-II3, however the data are not shown. 
 
Figure 17: Detection of cellular uptake of Ru-II3 at early and late time points after treatment. 
Ru-II3 found intracellularly through flow cytometry on FL3-H at 60 min, 2, 4, 6 & 24h post treatment. The emission 
fluorescence is near 600 nm. 
 
 
Figure 18: Detection of cellular uptake of Ru-II2-III at early and late time points after treatment. 
Ru-II2-III found intracellularly through flow cytometry on FL3-H at 2, 4, 6 & 24h post treatment. The emission 
fluorescence is near 600 nm. 
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3.5 Cytotoxicity of the Final (Tris-) Complexes in the Dark 
The final (Tris-) complexes were tested on the 6 solid tumor cell lines using the cell 
viability assay. The effect of cisplatin was also tested on the same cell lines and the 
results were used as positive control as shown in figures 17, 18, 19, 20, 21 & 23. Data 
showed that all final complexes that have more L-II ligands conjugated to the Ru(II) 
metal had a significant potency against solid tumor cell lines in the dark, especially Ru-
II3 more than Ru-II2-III. These 2 final compounds do not bear a negative charge in their 
structure. In addition, the tested cell lines had a higher sensitivity to Ru-II3, as their IC50 
values were in the low µM range, and in the case of SF268, IC50 values reached the low 
nM range, while the other 2 final complexes, Ru-II-III2 and Ru-III3, showed little or no 
effect as expected (figure 23 & table 2). Regarding A549 and Caco2 cell lines, they 
showed resistance to cisplatin while having significant sensitivity to Ru-II3, and in the 
case of A549 to Ru-II2-III as shown in figures 17 and 19, respectively. 
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Figure 19: Cytotoxic effect of the final Ru(II) complexes vs. ligands, precursors and cisplatin on A549 solid tumor 
cell line at 72h in the dark. 
 Nonlinear regression curves for the cytotoxicity of L-II, L-III, Ru-II, Ru-III, Ru-II3, Ru-II2-III, Ru-II-III2, Ru-III3 
and cisplatin       vs DMSO on A549. 
 
 
 
 
Figure 20: Cytotoxic effect of the final Ru(II) complexes vs. ligands, precursors and cisplatin on B16 solid tumor 
cell line at 72h in the dark. 
Nonlinear regression curves for the cytotoxicity of L-II, L-III, Ru-II, Ru-III, Ru-II3, Ru-II2-III, Ru-II-III2, Ru-III3 
and cisplatin vs DMSO on B16.  
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Figure 21: Cytotoxic effect of the final Ru(II) complexes vs. ligands, precursors and cisplatin on Caco2 solid 
tumor cell line at 72h in the dark. 
Nonlinear regression curves for the cytotoxicity of L-II, L-III, Ru-II, Ru-III, Ru-II3, Ru-II2-III, Ru-II-III2, Ru-III3 
and cisplatin vs DMSO on Caco2. 
 
 
 
Figure 22: Cytotoxic effect of the final Ru(II) complexes vs. ligands, precursors and cisplatin on MCF-7 solid 
tumor cell line at 72h in the dark. 
Nonlinear regression curves for the cytotoxicity of L-II, L-III, Ru-II, Ru-III, Ru-II3, Ru-II2-III, Ru-II-III2, Ru-III3 
and cisplatin vs DMSO on MCF-7. 
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Figure 23: Cytotoxic effect of the final Ru(II) complexes vs. ligands, precursors and cisplatin on MDA-MB-231 
solid tumor cell line at 72h in the dark. 
Nonlinear regression curves for the cytotoxicity of L-II, L-III, Ru-II, Ru-III, Ru-II3, Ru-II2-III, Ru-II-III2, Ru-III3 
and cisplatin vs DMSO on MDA-MB-231. 
 
 
 
 
  Figure 24: Cytotoxic effect of the final Ru(II) complexes vs. ligands, precursors and cisplatin on SF268 solid 
tumor cell line at 72h in the dark. 
  Nonlinear regression curves for the cytotoxicity of L-II, L-III, Ru-II, Ru-III, Ru-II3, Ru-II2-III, Ru-II-III2, Ru-III3 
and cisplatin vs DMSO on SF268. 
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Figure 25: L-II, Ru-II and the final complexes Ru-II3 & Ru-II2-III (that have more L-II ligands conjugated) 
show potency against solid tumor cell lines in the dark. 
IC50 (µM) at 72h of the different compounds and cisplatin on 6 solid tumor cell lines.  
 
 
 
Table 2: Average IC50 (µM) at 72h 
 L-II Ru-
II 
L-
III 
Ru-
III 
 Ru-
II3 
Ru-II2-
III 
Ru-II-
III2 
Ru-
III3 
A549 2 16 >200 >200 1.5 19 >200 >200 
B16 2.5 3.5 >200 >200 1.5 14 >200 >200 
Caco2 >200 20 >200 >200 17 >200 >200 >200 
MCF-7 >200 18 >200 >200 3.5 >200 >200 >200 
MDA-
MB-231 
>200 15 >200 >200 3 >200 >200 >200 
SF268 0.5 1 >200 >200 1 13 >200 >200 
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3.6 Type of Cell Death Determination of the Action of the Final Ru(II) 
Complexes Active in the Dark 
The two final complexes that showed activity in the dark, as well as the other two 
inactive compounds, were applied on SF268 cell line, and flow cytometry was used to 
determine the type of cell death at 24h, 48h and 72h and cell cycle analysis at 72h as 
described earlier. 
Results showed that the type of cell death of Ru-II3 in the dark was non-apoptotic 
as observed in figure 26, at 24h, 48h and 72h since most of the cells were late 
apoptotic/necrotic and the caspase assay confirms the lack of apoptosis due to the 
absence of cascade activation. Same goes for Ru-II2-III where no signs of apoptosis 
were detected (Figure 27), whereas Ru-II-III2 and Ru-III3, as previously demonstrated in 
the previous experiments, showed no type of cell death as expected (figure 28). 
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Figure 26: Cell death caused by Ru-II3 is non-apoptotic in the dark. 
Annexin-PI at 24h (1), 48h (2) and 72h (3) & Caspase Activation at 48h (4) and 72h (5). SF268 Control (1A, 
2A &3A). Ru-II3 – 1.5 µM (1B, 2B & B) & 3 µM (1C, 2C & 3C). 
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Figure 27: Cell death caused by Ru-II2-III is non-apoptotic in the dark. 
Annexin-PI at 24h (1), 48h (2) and 72h (3) & Caspase Activation at 48h (4) and 72h (5). SF268 Control (1A, 2A &3A). 
Ru-II2III – 12 µM (1B, 2B & B) & 24 µM (1C, 2C & 3C). 
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Figure 28: No cell death caused by Ru-II-III2 and Ru-III3 in the dark. 
Annexin-PI at 72h (1A-B & 2A-B) & Caspase Activation at 72h (1D & 2D). SF268 Control (1A & 2A). Ru-II-III2 – 
10 µM (1B) & 20 µM (2B)   and Ru-III3 – 7 µM (1C) & 14 µM (2C) (Random dosages) 
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3.7 Cell Cycle Analysis of the Action of the Final Ru(II) Complexes Active 
in the Dark 
Cell cycle analysis data in figure 29 are preliminary results. This experiment is still a 
work in progress. However, it was shown that there is a significant decrease of cell cycle 
arrest at G1 at high concentrations of Ru-II3 & Ru-II2-III at 72h when tested on SF268 
cell line. In contrast, Ru-II-III2 and Ru-III3 did not show this decrease as expected since 
they are inert in the dark. These data are non-conclusive and need to be further 
elucidated. 
 
Figure 29: Preliminary results of Cell cycle analysis of the 4 (Tris-) compounds in the dark. 
Cell Cycle Analysis – PI Staining at 72h. SF268 Control (A, D, G & K). Ru-II3 – 1.5 µM (B) & 3 µM (C), Ru-II2III – 
3 µM (E) & 6 µM (F), Ru-II-III2 – 7 µM (H) & 14 µM (I), Ru-III3 – 1 µM (L) & 2 µM (M). 
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3.8 Cytotoxicity of the Final (Tris-) Compounds with Light Activation 
against SF268 
The 4 final (Tris-) compounds were tested on SF268 cell line in the dark and after 
exposure to blue light as described above at 6h, 12h and 24h post-treatment. Previous data 
showed that only Ru-II3 and Ru-II2-III had a cytotoxic effect on cells in the dark and the 
other 2 were inert. However, upon photo-activating the 4 compounds at the different time 
points as mentioned above, all of them showed activity including the DMSO solvent (figure 
26). Cell death was observed in the cells exposed to DMSO alone at the earliest time points 
of photo-activation, and its “cytotoxic effect” appeared to diminish at the later time points, 
specifically at 24h post-treatment light activation (figure 29).  
In table 3, results show the differences between the 4 compounds’ IC50 values and in 
figures 31 & 32 the significant increase or initiation of their cytotoxic action at the 24h 
time point. In the case of Ru-II3 and Ru-II2-III, their potent activity increased, occurring 
at earlier time points, whereas Ru-II-III2 and Ru-III3 acquired potency.   
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Figure 30: Effect of all final complexes is significantly potentiated after exposure to blue light. 
Nonlinear regression curves for the cytotoxicity of Ru-II3, Ru-II2-III, Ru-II-III2 & Ru-III3 vs DMSO (solvent) on 
SF268 in the dark (A), with light activation at T=6h (B), at T=12h (C) and at T=24h (D). All readings of the cell 
viability experiment were done at 72h. 
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Figure 31: Comparison of the effect of all final complexes in the dark and after exposure to blue light 24h 
posttreatment. 
Nonlinear regression curves for the cytotoxicity of Ru-II3, Ru-II2-III, Ru-II-III2 & Ru-III3, dark vs light at 24h on 
SF268.  
All readings of the cell viability experiment were done at 72h. 
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Figure 32: IC50 values in the nM and µM range after activating all of the final complexes at 24h post-treatment. 
 
Table 3: Average IC50 (µM) at 72h – Dark vs Light @ 24h – SF268 cell line. 
SF268 
Compounds DARK 
BLUE 
LIGHT 
10V/30 min 
@6h 
BLUE 
LIGHT 
10V/30 min 
@ 12h 
BLUE 
LIGHT 
10V/30 min 
@24h 
Photo-
toxicity 
index @ 24h 
Ru-II3 1.5 0.3 0.2 0.03  50 
Ru-II2-III 12 0.8 7 3  4.5 
Ru-II-III2 >200 0.8 2.5 7  >200 
Ru-III3 >200 0.3 1 0.6  >200 
The Photo-toxicity Index is the ratio of the IC50 value in the dark to that in the light. 
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3.9 Type of Cell Death Determination of the Action of the Final Ru(II) 
Complexes Active in the Light 
     The 4 final complexes were applied on SF268 cell line, and flow cytometry was 
used to determine the type of cell death at 72h as described earlier, with photo-activation 
using the blue light at 24h post-treatment.  
Results showed that the type of cell death of Ru-II3 in the dark was also non-
apoptotic as shown in figure 33, at 72h, since most of the cells were late apoptotic/necrotic. 
Also, the caspase assay showed no caspase cascade activation thus indicating no apoptosis. 
In the case of Ru-II2-III, no signs of apoptosis were detected at 72h (Figure 34) since the 
majority of cells were necrotic and lack of apoptosis was confirmed by the caspase assay. 
Same goes for the inert compounds in the dark, once applying blue light on plates treated 
with Ru-II-III2 and Ru-III3 at 24h as previously stated, these compounds were activated 
and showed no sign of apoptosis (figure 34).  
 
 
 Figure 33: Cell death caused by Ru-II3 is predominantly non-apoptotic after blue light exposure at 24h. 
Annexin-PI (A-C) & Caspase Activation (D) at 72h. SF268 Control (1A). Ru-II3 – 0.1 µM (1B) & 0.2 µM (1C). 
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Figure 34: Cell death caused by Ru-II2-III, Ru-II-III2 and Ru-III3 is non-apoptotic after blue light exposure at 
24h. 
Annexin-PI at 72h (A-C, E-G, I-K) & Caspase Activation at 72h (D, H & L). SF268 Control (A, E &I). Ru-II2III – 3 
µM (B) & 6 µM (C), Ru-II-III2 – 7 µM (F) & 14 µM (G), Ru-III3 – 1 µM (J) & 2 µM (K). 
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3.10 Cell Cycle Analysis of the Action of the Final Ru(II) Complexes 
Active in the Light 
Cell cycle analysis data shown in figure 35 are preliminary results. This experiment is 
still a work in progress. However, it was shown that there is a significant increase of cell 
cycle arrest at sub-G and significant decrease at G1 at high concentrations of all the (Tris-
) compounds at 72h when tested on SF268 cell line. These data are non-conclusive and 
need to be further elucidated. 
 
Figure 35: Preliminary results of Cell cycle analysis of the 4 (Tris-) compounds after photo-activation. 
Cell Cycle Analysis – PI Staining at 72h. SF268 Control (A, D, G & K). Ru-II3 – 0.1 µM (B) & 0.2 µM (C), Ru-II2III 
– 3 µM (E) & 6 µM (F), Ru-II-III2 – 7 µM (H) & 14 µM (I), Ru-III3 – 1 µM (L) & 2 µM (M). 
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CHAPTER FOUR 
Discussion 
 
4.1 Establishing a Structure-Activity Relationship in the Dark 
Cell viability assays were applied on the ligand-free Ru(II) metal control, the free 
phenanthroline and bipyridine derivative ligands along with their corresponding Ru(II) 
metal complexes  in order to test whether a cytotoxic effect is detected against the 6 solid 
tumor cell lines. 
These different compounds differ from each other in their structures as followed: 
L-I & Ru-I are hydrophobic and bulky, L-II & Ru-II are more hydrophobic and 
bulkier, respectively. L-III and Ru-III, with the exception of having negatively-charged 
sulfonated groups on the phenyls, have more or less a similar structure to L-II and Ru-II, 
respectively. The addition of these sulfonated groups attributed an anionic characteristic to 
these compounds, causing them to be repulsed by the negatively charged backbone of the 
DNA, thus inhibiting their intercalation. The results obtained in the cytotoxicity assays 
confirmed this theory by showing an effect similar to that of DMSO (inert) on all the tested 
cell line. However, L-I, L-II, Ru-I and Ru-II showed different sensitivity on the tested cell 
lines, whereas L-IV was selective to only one cell line (B16). This leads to the assumption 
that L-I, L-II and L-IV have the selective ability to intercalate DNA in specific solid tumors 
cell lines. When conjugating 2 L-I ligands to Ru-I, not the same significant activity was 
displayed, same goes for conjugating 2 L-II ligands to Ru-II, but when conjugating 2 L-IV 
ligands to Ru-IV, no activity was detected. Thus, diphenylphenanthroline, a molecule that 
results when 2 phenyl groups are added to phenanthroline, can significantly increase the 
activity of phenanthroline-derived compounds to become more effective DNA 
intercalating agents.  
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Table 4: Binding constants for trisbidentate complexes of Ru(II). 
 
(From Clarke, 2002) 
Trisbidentate complexes of Ru(II), also known as molecules containing an Ru core 
conjugated to three ligands have been reviewed in 2002 by Clarke et al. Some of these 
compounds were reported as poor DNA intercalators: [Ru(bpy)3]
2+ (Ru core connected to 
three bipyridine ligands) and [Ru(phen)3]
2+ (Ru core connected to three phenanthroline 
ligands) (Table 4). The results obtained are in accordance with what was stated earlier as 
the compounds tested, Ru-IV {[Ru(bpy)2Cl2]
2+} and Ru-I {[Ru(phen)2Cl2]
2+}, that share 
high similarities with [Ru(bpy)3]
2+ and [Ru(phen)3]
2, respectively, were not DNA 
intercalating agents since they showed low or no activity against the tested cell lines (figure 
13). In addition, when one phenanthroline and two bipyridine molecules are connected to 
the Ru metal core forming [Ru(bpy)2phen]
2+ showed no DNA intercalating potential. At 
the same time, another similar compound, where the phenanthroline ligand is replaced with 
a diphenylphenanthroline ligand {[Ru(bpy)2dip]
2+} was an effective DNA intercalator 
(Table 4). The results obtained confirmed what was state previously since 
{[Ru(dip)2Cl2]
2+}, in which the Ru core is connected to two diphenylphenanthroline 
ligands, showed significant activity against the majority of the tested cell lines. All the 
previous data and results indicate that one diphenylphenanthroline ligand connected to the 
Ru core is enough to confer intercalative activity. In addition, Clarke et al (2002) showed 
that some combinations of ligands are also active in intercalating DNA (table 4). 
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Figure 36: Structures of N-heteroaromatic ligands. (From Clarke M. J., 2002) 
The general structure-activity relationship is still conserved in the final (Tris-) 
compounds in the dark. The compounds bearing 3 L-II and 2 L-II ligands in their structure 
showed very high potency, as predicted since they are cationic and neutral, respectively. 
This allows them to play a significant role as intercalating agents. Whereas the 2 other 
(Tris-) compounds bearing more L-III ligands are anionic and unable to intercalate the 
DNA.  
 
 
 
 51 
 
4.2 Type of Cell Death and Cell Cycle Analysis of the Final (Tris-) 
Compounds in the Dark 
Our data obtained from the flow cytometry assay showed a non-apoptotic type of cell 
death of the treated SF268 cells with Ru-II3 and Ru-II2-III in the dark. Additional 
investigation and experiments should be done to further understand the type of cell death 
elucidated by these 2 compounds on solid tumors (necrosis, autophagy, test for apoptotic 
markers by western blots,…), as well as test again for any cell cycle arrest occurring in 
cells when treated with the different compounds. 
4.3 Photo-Activation and an Activity Profile that does not obey the 
Structure-Activity Relationship 
When photo-activated with blue light, the activity of the anionic compounds (Ru-II-
III2 and Ru-III3) was altered, thereby acquiring potency against SF268 cell lines. Thus, 
these complexes are very promising for photodynamic therapies (PDT) since in the dark, 
they act as inactive pro-drugs, and this inert activity is terminated once exposed to blue 
light. A suggested mechanism is that, upon photo-activation, reactive oxygen species are 
liberated, causing this cytotoxic effect. This still needs to be investigated by additional 
biological experiments such as detecting levels of ROS release by flow cytometry assay or 
others. 
4.4 Type of Cell Death and Cell Cycle Analysis of the Final (Tris-) 
Compounds after Photo-Activation 
Our data obtained from the flow cytometry assay showed also a non-apoptotic type 
of cell death of the treated SF268 cell lines with all 4 final (Tris-) compounds after exposure 
to the blue light. Additional investigation and experiments should be done to further 
understand the type of cell death elucidated by these 4 complexes on solid tumors (necrosis, 
autophagy, test for apoptotic markers by western blots,…), as well as check for any cell 
cycle arrest occurring in cells when treated with the different compounds. 
 
 52 
 
4.5 Conclusion 
In conclusion, different ruthenium precursors, final complexes and free 
phenanthroline- or bipyridine-derived ligands were tested against 6 solid tumor cell lines. 
Mainly, the Ru-II precursor has shown most potency on all cell lines and specifically on 
SF268, since it bears two diphenylphenanthroline ligands, while the rest of the precursors 
showed low potency or none. As for the free ligands, significant activity was detected 
with L-II (diphenylphenanthroline) on most of the cell lines while L-I (phenanthroline) 
showed less activity on fewer cell lines, whereas L-III was biologically inert after adding 
the sulfonate groups to its structure. L-IV showed no activity at all, similarly to its 
precursor. These data suggest that the phenanthroline-derived metal-based complexes act 
as DNA intercalating agents and exert their potent action. And since the unconjugated 
Ru(II) metal core alone did not affect any of the tested cell lines, it can be deduce that 
any activity detected is due to the ligands that are bound to the ruthenium metal. 
Moreover, the four final tris-bidentate compounds, Ru-II3, Ru-II2-III, Ru-II-III2 and Ru-
III3, were studied in the dark and after exposure to blue light. In the dark, only Ru-II3 was 
active against all the tested cell lines, Ru-II2-III showed moderate toxicity against three 
cell lines (A549, B16, and SF268), while the others showed no effect. After exposure of 
SF268 treated cells to the blue light, all four compounds showed high levels of potency, 
including Ru-II-III2 and Ru-III3 that were biologically inert in the dark. It is assumed that 
the (Tris-) final compounds’ cytotoxic action is due to the release of Reactive Oxygen 
Species (ROS), thus affecting the cells’ metabolism and causing DNA damage, thereby 
leading to cell death. Notably, Ru-II-III2 and/or Ru-III3 seem promising in being 
successfully developed as photo-dynamic therapeutic agents, due to the absence of 
potency when in the dark and their sudden switch to activity when photo-activated.  
Further investigation and studies need to be done in order to further understand their 
detailed underlying mechanisms of action in the dark and when exposed to blue light by 
examining at which stage of mitosis cell cycle arrest is occurring, as well as the type of 
cell death they cause. Finally, these studies will constitute a beginning in the quest of 
finding the most selective and potent complex, and the possibility of new targeted 
photodynamic therapies against solid tumors. 
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